Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: The fracture intervention trial

Theresa H M Keegan, Ann V. Schwartz, Douglas C. Bauer, Deborah E. Sellmeyer, Jennifer L. Kelsey

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

OBJECTIVE - Alendronate sodium (ALN) increases bone mineral density (BMD) in heterogeneous populations of postmenopausal women, but its effect is unknown in women with type 2 diabetes. The objective of this project was to compare changes in BMD during 3 years of ALN treatment versus placebo in diabetic women. RESEARCH DESIGN AND METHODS - We used data from the Fracture Intervention Trial, a randomized blinded placebo-controlled trial conducted at 11 centers in which 6,458 women aged 54-81 years with a femoral neck BMD of ≤0.68 g/cm 2 were randomly assigned to either placebo or 5 mg/day ALN for 2 years, followed by 10 mg/day for the remainder of the trial. BMD was measured by dual-energy X-ray absorptiometry. Type 2 diabetes (n = 297) was defined by self-report, use of insulin or other hypoglycemic agents, or a random nonfasting glucose value ≥200 mg/dl. RESULTS - In diabetic women, 3 years of ALN treatment was associated with increased BMD at all sites studied, including 6.6% at the lumbar spine and 2.4% at the hip, whereas women in the placebo group experienced a decrease in BMD at all sites except the lumbar spine. The safety/tolerability of ALN was similar to placebo, except for abdominal pain, which was more likely in the ALN group. CONCLUSIONS - ALN increased BMD relative to placebo in older women with type 2 diabetes and was generally well tolerated as a treatment for osteoporosis. Increases in BMD with ALN therapy compared with placebo were similar between women with and without diabetes.

Original languageEnglish (US)
Pages (from-to)1547-1553
Number of pages7
JournalDiabetes Care
Volume27
Issue number7
DOIs
StatePublished - Jul 2004
Externally publishedYes

Fingerprint

Alendronate
Bone Remodeling
Bone Density
Biomarkers
Placebos
Type 2 Diabetes Mellitus
Spine
Femur Neck
Photon Absorptiometry
Therapeutics
Hypoglycemic Agents
Self Report
Abdominal Pain
Osteoporosis
Hip
Research Design
Insulin
Safety
Glucose

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women : The fracture intervention trial. / Keegan, Theresa H M; Schwartz, Ann V.; Bauer, Douglas C.; Sellmeyer, Deborah E.; Kelsey, Jennifer L.

In: Diabetes Care, Vol. 27, No. 7, 07.2004, p. 1547-1553.

Research output: Contribution to journalArticle

Keegan, Theresa H M ; Schwartz, Ann V. ; Bauer, Douglas C. ; Sellmeyer, Deborah E. ; Kelsey, Jennifer L. / Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women : The fracture intervention trial. In: Diabetes Care. 2004 ; Vol. 27, No. 7. pp. 1547-1553.
@article{a9d65315b7cd41a4a8f595109ced545f,
title = "Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: The fracture intervention trial",
abstract = "OBJECTIVE - Alendronate sodium (ALN) increases bone mineral density (BMD) in heterogeneous populations of postmenopausal women, but its effect is unknown in women with type 2 diabetes. The objective of this project was to compare changes in BMD during 3 years of ALN treatment versus placebo in diabetic women. RESEARCH DESIGN AND METHODS - We used data from the Fracture Intervention Trial, a randomized blinded placebo-controlled trial conducted at 11 centers in which 6,458 women aged 54-81 years with a femoral neck BMD of ≤0.68 g/cm 2 were randomly assigned to either placebo or 5 mg/day ALN for 2 years, followed by 10 mg/day for the remainder of the trial. BMD was measured by dual-energy X-ray absorptiometry. Type 2 diabetes (n = 297) was defined by self-report, use of insulin or other hypoglycemic agents, or a random nonfasting glucose value ≥200 mg/dl. RESULTS - In diabetic women, 3 years of ALN treatment was associated with increased BMD at all sites studied, including 6.6{\%} at the lumbar spine and 2.4{\%} at the hip, whereas women in the placebo group experienced a decrease in BMD at all sites except the lumbar spine. The safety/tolerability of ALN was similar to placebo, except for abdominal pain, which was more likely in the ALN group. CONCLUSIONS - ALN increased BMD relative to placebo in older women with type 2 diabetes and was generally well tolerated as a treatment for osteoporosis. Increases in BMD with ALN therapy compared with placebo were similar between women with and without diabetes.",
author = "Keegan, {Theresa H M} and Schwartz, {Ann V.} and Bauer, {Douglas C.} and Sellmeyer, {Deborah E.} and Kelsey, {Jennifer L.}",
year = "2004",
month = "7",
doi = "10.2337/diacare.27.7.1547",
language = "English (US)",
volume = "27",
pages = "1547--1553",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "7",

}

TY - JOUR

T1 - Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women

T2 - The fracture intervention trial

AU - Keegan, Theresa H M

AU - Schwartz, Ann V.

AU - Bauer, Douglas C.

AU - Sellmeyer, Deborah E.

AU - Kelsey, Jennifer L.

PY - 2004/7

Y1 - 2004/7

N2 - OBJECTIVE - Alendronate sodium (ALN) increases bone mineral density (BMD) in heterogeneous populations of postmenopausal women, but its effect is unknown in women with type 2 diabetes. The objective of this project was to compare changes in BMD during 3 years of ALN treatment versus placebo in diabetic women. RESEARCH DESIGN AND METHODS - We used data from the Fracture Intervention Trial, a randomized blinded placebo-controlled trial conducted at 11 centers in which 6,458 women aged 54-81 years with a femoral neck BMD of ≤0.68 g/cm 2 were randomly assigned to either placebo or 5 mg/day ALN for 2 years, followed by 10 mg/day for the remainder of the trial. BMD was measured by dual-energy X-ray absorptiometry. Type 2 diabetes (n = 297) was defined by self-report, use of insulin or other hypoglycemic agents, or a random nonfasting glucose value ≥200 mg/dl. RESULTS - In diabetic women, 3 years of ALN treatment was associated with increased BMD at all sites studied, including 6.6% at the lumbar spine and 2.4% at the hip, whereas women in the placebo group experienced a decrease in BMD at all sites except the lumbar spine. The safety/tolerability of ALN was similar to placebo, except for abdominal pain, which was more likely in the ALN group. CONCLUSIONS - ALN increased BMD relative to placebo in older women with type 2 diabetes and was generally well tolerated as a treatment for osteoporosis. Increases in BMD with ALN therapy compared with placebo were similar between women with and without diabetes.

AB - OBJECTIVE - Alendronate sodium (ALN) increases bone mineral density (BMD) in heterogeneous populations of postmenopausal women, but its effect is unknown in women with type 2 diabetes. The objective of this project was to compare changes in BMD during 3 years of ALN treatment versus placebo in diabetic women. RESEARCH DESIGN AND METHODS - We used data from the Fracture Intervention Trial, a randomized blinded placebo-controlled trial conducted at 11 centers in which 6,458 women aged 54-81 years with a femoral neck BMD of ≤0.68 g/cm 2 were randomly assigned to either placebo or 5 mg/day ALN for 2 years, followed by 10 mg/day for the remainder of the trial. BMD was measured by dual-energy X-ray absorptiometry. Type 2 diabetes (n = 297) was defined by self-report, use of insulin or other hypoglycemic agents, or a random nonfasting glucose value ≥200 mg/dl. RESULTS - In diabetic women, 3 years of ALN treatment was associated with increased BMD at all sites studied, including 6.6% at the lumbar spine and 2.4% at the hip, whereas women in the placebo group experienced a decrease in BMD at all sites except the lumbar spine. The safety/tolerability of ALN was similar to placebo, except for abdominal pain, which was more likely in the ALN group. CONCLUSIONS - ALN increased BMD relative to placebo in older women with type 2 diabetes and was generally well tolerated as a treatment for osteoporosis. Increases in BMD with ALN therapy compared with placebo were similar between women with and without diabetes.

UR - http://www.scopus.com/inward/record.url?scp=3042757781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042757781&partnerID=8YFLogxK

U2 - 10.2337/diacare.27.7.1547

DO - 10.2337/diacare.27.7.1547

M3 - Article

C2 - 15220226

AN - SCOPUS:3042757781

VL - 27

SP - 1547

EP - 1553

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 7

ER -